Assessment of feasibility, economics, and market potential for a molten salt system at 1000/sup 0/F reheat steam: feasibility, economics, and market potential

As a result of the Advanced Central Receiver (ACR) Phase I systems studies, Martin-Marietta Corporation (MMC) developed a conceptual design employing 1050/sup 0/F molten salt and a 950/sup 0/F/950/sup 0/F reheat turbine. This concept appears to have the potential for providing higher steam conditions leading to higher performance and wider market application. This report presents the results of a preliminary investigation of the system to determine the feasibility of providing 1000/sup 0/F/1000/sup 0/F steam and the impact of the required design modifications on the system performance, cost, and market potential for solar repowering. Two modified designs are investigated. In one modified design, the temperature of the molten salt is the same as in the MMC baseline design (1050/sup 0/F), but the steam generators have been modified to provide 1000/sup 0/F/1000/sup 0/F steam. In the other modified design, the enhanced steam conditions are obtained using molten salt at a temperature of 1100/sup 0/F

Search for human herpesvirus 6 and human cytomegalovirus in bronchoalveolar lavage from patients with human immunodeficiency virus-1 and respiratory disorders

Virus isolation and viral DNA detection by the polymerase chain reaction were used to investigate the presence of human herpesvirus 6 (HHV-6) and human cytomegalovirus (HCMV) in bronchoalveolar lavage from 34 human immunodeficiency virus-1 (HIV-1)-infected patients with respiratory disorders. The aim was to assess the presence of reactivated HHV-6 in lung tissues for a subsequent evaluation of the frequency of virus involvement in respiratory clinical manifestations in the course of HIV-1 infection. Bronchoalveolar lavage samples were tested for the presence of HCMV, as a routine investigation within a protocol monitoring opportunistic infections in symptomatic HIV-1 patients. Whereas HCMV DNA was detected by the polymerase chain reaction in 12 bronchoalveolar lavage specimens, 10 of which were also positive for virus isolation, all samples were negative for HHV-6 by both virological procedures. The HHV-6 DNA finding in bronchoalveolar lavage from an HIV-1-seronegative patient with renal carcinoma, investigated accidentally together with the bronchoalveolar lavage specimens from HIV-1 seropositive patients, stressed the HHV-6 polymerase chain reaction-negative results in the bronchoalveolar lavage samples under study. It is concluded that the lung may be a target organ for HCMV infection in HIV-1-seropositive patients affected by respiratory symptoms but that this does not seem to be the case for HHV-6